Eli Lilly Reports Phase 2 Data for Atezolizumab in Myasthenia gravis

Eli Lilly today announced Phase 2 results for atezolizumab in patients with myasthenia gravis. The study demonstrated that atezolizumab achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of myasthenia gravis and support the continued development of atezolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.